Pulse Stimulation Device Tested for Early Alzheimer's Disease
Tests a non-invasive pulse device against a sham device in early Alzheimer's disease.
Plain-language title generated from the registry record
Registry title: Transcranial Pulse Stimulation for Alzheimer's Disease
Key facts
- Where
- Hong Kong, Hong KongSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 60 and 90 years old?
Source: NCT07143734, who can take part
Where in Hong Kong
- Department of Medicine & Therapeutics, Faculty of Medicine, The Chinese UNiversity of Hong KongHong Kong, Hong KongTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Chinese University of Hong Kong
- Trial code
- NCT07143734
- Record updated
- 16 September 2025
- Original description
TPS is a non-invasive therapeutic modality that uses focused, low-energy pulse stimulation to stimulate tissue regeneration and reduce inflammation. In the context of neurological disorders, it is hypothesized that TPS can modulate neuronal activity, enhance synaptic plasticity, and reduce neuroinflammation. It is a relatively new application in neurological disease treatment and is still under intense investigation.Read full original descriptionShow less
A Pilot Randomized Placebo-Controlled Trial of Transcranial Pulse Stimulation (TPS) in Early Alzheimer's Disease (AD) Subjects
TPS is a non-invasive therapeutic modality that uses focused, low-energy pulse stimulation to stimulate tissue regeneration and reduce inflammation. In the context of neurological disorders, it is hypothesized that TPS can modulate neuronal activity, enhance synaptic plasticity, and reduce neuroinflammation. It is a relatively new application in neurological disease treatment and is still under intense investigation.
Inclusion: Adults who have been clinically diagnosed with Alzheimer's Disease in the early stage 2-6a according to the Functional Assessment Staging Test (In Appendix A); The mental capacity to give informed consent for research is made by an experienced geriatrician based on Appendix A; Aged 60-90 years old; Able to make informed consent under assistance, which is witnessed and signed by a family caregiver.
Exclusion: Presence of any metal implants in the brain; Major neurological conditions, including:; Hemophilia or other blood clotting disorders; History of thrombosis; Cannot understand Chinese; Mentally incapacitated, unable to provide informed consent; Inability to remain still for 30 minutes; Lack of available family caregiver to answer questionnaires; Alcohol or substance dependence; Brain tumor; Brain aneurysm.